0001209191-23-004223.txt : 20230120
0001209191-23-004223.hdr.sgml : 20230120
20230120160536
ACCESSION NUMBER: 0001209191-23-004223
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230119
FILED AS OF DATE: 20230120
DATE AS OF CHANGE: 20230120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duncan Jason
CENTRAL INDEX KEY: 0001741553
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33451
FILM NUMBER: 23540999
MAIL ADDRESS:
STREET 1: C/O ALBIREO PHARMA, INC.
STREET 2: 10 POST OFFICE SQUARE, SUITE 502 SOUTH
CITY: BOSTON
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALBIREO PHARMA, INC.
CENTRAL INDEX KEY: 0001322505
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 POST OFFICE SQUARE
STREET 2: SUITE 502 SOUTH
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: 857-415-4774
MAIL ADDRESS:
STREET 1: 10 POST OFFICE SQUARE
STREET 2: SUITE 502 SOUTH
CITY: BOSTON
STATE: MA
ZIP: 02109
FORMER COMPANY:
FORMER CONFORMED NAME: Biodel Inc
DATE OF NAME CHANGE: 20050331
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-19
0
0001322505
ALBIREO PHARMA, INC.
ALBO
0001741553
Duncan Jason
C/O ALBIREO PHARMA, INC.
53 STATE STREET, 19TH FLOOR
BOSTON
MA
02109
0
1
0
0
Chief Legal Officer and GC
Common Stock
2023-01-19
4
S
0
938
43.9044
D
14374
D
Shares sold pursuant to a Rule 10b5-1 arrangement established in October 2019 to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Represents 2,867 shares of common stock and 11,507 restricted stock units. Includes 381 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on November 30, 2022.
/s/ Jason Duncan
2023-01-20